BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Ono Pharmaceutical (4528.T) announced that it has submitted an application for the manufacturing and marketing approval of ripretinib or DCC-2618, developed by Deciphera Pharmaceuticals, for the indication of gastrointestinal stromal tumor that has progressed following cancer chemotherapy. The application is based on the results of the INVICTUS study, a global Phase 3 clinical study.
Deciphera, a member of Ono Pharmaceutical Co., is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines and providing hope to people living with cancer, neurologic and autoimmune disease.
Shares of Ono Pharma are trading at 2,476 yen, up 0.61%.
For More Such Health News, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
